Trinity Biotech plc (NASDAQ:TRIB) Short Interest Down 11.9% in February

Trinity Biotech plc (NASDAQ:TRIBGet Rating) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 34,000 shares, a decline of 11.9% from the February 13th total of 38,600 shares. Based on an average daily volume of 26,100 shares, the short-interest ratio is currently 1.3 days.

Institutional Investors Weigh In On Trinity Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in TRIB. Hunter Associates Investment Management LLC grew its stake in Trinity Biotech by 1.5% in the 4th quarter. Hunter Associates Investment Management LLC now owns 1,823,633 shares of the company’s stock valued at $1,809,000 after buying an additional 26,443 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Trinity Biotech by 2.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company’s stock valued at $1,842,000 after purchasing an additional 34,900 shares during the period. Whitefort Capital Management LP raised its stake in shares of Trinity Biotech by 1,067.8% during the 1st quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock valued at $434,000 after purchasing an additional 374,449 shares during the period. Virtu Financial LLC bought a new position in Trinity Biotech in the 1st quarter worth about $40,000. Finally, Atria Wealth Solutions Inc. increased its stake in Trinity Biotech by 38.9% in the 4th quarter. Atria Wealth Solutions Inc. now owns 34,300 shares of the company’s stock worth $34,000 after acquiring an additional 9,600 shares during the last quarter. Hedge funds and other institutional investors own 18.41% of the company’s stock.

Trinity Biotech Stock Down 0.8 %

TRIB stock opened at $0.97 on Monday. The stock has a market capitalization of $36.97 million, a P/E ratio of -0.89 and a beta of 1.43. The company has a current ratio of 3.38, a quick ratio of 1.78 and a debt-to-equity ratio of 8.70. Trinity Biotech has a 12 month low of $0.91 and a 12 month high of $1.55. The firm has a 50-day moving average price of $1.06 and a 200-day moving average price of $1.15.

Trinity Biotech (NASDAQ:TRIBGet Rating) last posted its earnings results on Thursday, December 15th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.14). Trinity Biotech had a negative return on equity of 419.23% and a negative net margin of 42.21%. The company had revenue of $19.50 million during the quarter, compared to the consensus estimate of $19.50 million. As a group, equities research analysts anticipate that Trinity Biotech will post -0.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, started coverage on Trinity Biotech in a research note on Monday. They issued a “buy” rating on the stock.

About Trinity Biotech

(Get Rating)

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O’Caoimh and Denis R.

Read More

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with's FREE daily email newsletter.